India’s medical device industry stands at a genuine inflection point. Strong demand, active policy support, and rising domestic manufacturing have moved it from a largely import-dependent market toward a more balanced growth trajectory. The opportunity is real, but converting scale into sustained global competitiveness will depend on execution—especially in innovation, components, and regulatory maturity.

Current Growth Snapshot

As of 2025–2026, India’s medical devices market is estimated in the range of $14–16 billion. Independent assessments place it around $15.2 billion (Rubix Data Sciences) to approximately $16 billion (BCG analyses).

Domestic manufacturing’s share of local consumption has risen sharply—from roughly 20% in 2022 to about 45% in 2025—growing at over 40% CAGR in recent years. This shift reflects progress under the Production Linked Incentive (PLI) scheme and medical device parks.

Exports reached about $4.1 billion in FY25, with strength concentrated in consumables (nearly half of recent export value in some periods). Key destinations include the United States and Germany. Imports, however, remain substantially higher—estimated at $8.6 billion or more in recent data—leaving the sector 70–80% import-dependent for advanced and high-technology devices such as imaging systems and certain implants.

The industry comprises several hundred manufacturers (estimates range around 800 and higher when counting licensed entities more broadly), with manufacturing hubs in Uttar Pradesh, Maharashtra, Haryana, Karnataka and others. Private equity and venture interest has also increased, with average deal sizes rising notably in recent years.

Key Drivers of Recent Momentum

Several structural forces are at work:

  • Rising healthcare demand — Expansion of hospital and diagnostic infrastructure into Tier-2 and Tier-3 cities, higher insurance penetration (including Ayushman Bharat), a growing burden of non-communicable diseases, an ageing population, and medical tourism all support volume growth across consumables, diagnostics, and mid-tech equipment.
  •  — The National Medical Devices Policy 2023 provides a framework aimed at self-reliance, quality, innovation, and a long-term target of 10–12% global market share. Complementary measures include the PLI scheme (₹3,420 crore outlay, 5% incentive on incremental sales for targeted high-import segments), promotion of medical device parks, MedTech Mitra for regulatory and innovation support, and 100% FDI under the automatic route.
  • PLI outcomes — Multiple projects have been approved and commissioned, enabling domestic production of MRI and CT systems, linear accelerators, mammography units, certain implants, dialysis products and other previously import-heavy categories. Cumulative eligible sales and investments have grown meaningfully, though the scheme’s performance period runs through FY2026–27.
  • Cost and supply-chain positioning — India retains labour-cost advantages relative to developed markets and benefits from global “China+1” diversification trends and evolving free-trade agreements.

These factors have delivered measurable capacity addition and a clearer policy signal than existed a few years earlier.

Persistent Challenges

Growth has not eliminated structural weaknesses:

  • High-end technology gap — India remains heavily reliant on imports for complex imaging, certain cardiovascular devices, advanced diagnostics and critical components/raw materials. Domestic capability is strongest in low- to mid-technology consumables and selected implants.
  • Low R&D intensity — Indian manufacturers typically spend well below global MedTech leaders (often cited in the 1–4% of revenue range versus 6–15%+ elsewhere). Patent generation and novel device approvals (especially US FDA beyond 510(k) pathways) remain limited.
  • Regulatory and ecosystem friction — Sequential approvals, limited alignment with major international frameworks, testing infrastructure gaps, and procurement practices that sometimes favour established imports create hurdles, particularly for newer domestic players and innovative products. Industry bodies have also flagged competition from low-priced imports, including those routed through ASEAN channels.
  • After-sales and lifecycle support — As the installed base of equipment grows, servicing, calibration, maintenance and skilled technical support will become critical constraints if not addressed systematically.
  • Talent and capital depth — Manufacturing capacity has expanded faster than design and advanced-engineering capability in several segments.

These issues explain why import bills have continued to rise even as local production has increased, and why optimistic volume projections must be tempered by qualitative progress.

Future Opportunities

Projections vary by methodology, but the directional outlook is constructive:

  • Market size estimates for 2030 commonly fall in the $30–50 billion range (Rubix projects $50.1 billion at a high CAGR; BCG analyses point to a $41–44 billion opportunity). Longer-term visions include $80+ billion by the mid-2030s and as high as $250 billion by 2047 under ambitious scenarios.

BCG’s framing of three growth engines is useful:

  1. “India for India” — Serving rising domestic demand while substituting imports (largest near-term opportunity, especially in equipment and consumables, with IVD and devices scaling next).
  2. Export- and IP-led manufacturing — Building Indian-origin brands for regulated and emerging markets.
  3. Contract manufacturing — Capturing design, sub-assembly and production work as global OEMs diversify supply chains.

Additional openings include localisation of a short list of high-value devices (MRI systems and components, pacemakers, continuous glucose monitoring, advanced ultrasound, high-end analysers), deeper integration of software, AI and digital health, stronger clinical evidence generation, and preferential access through new trade agreements. Medical tourism and the expansion of private and public healthcare capacity further enlarge the addressable market.

The government’s stated ambition to raise India’s global market share from roughly 1.6% toward double digits over the longer term is ambitious but directionally consistent with the policy toolkit now in place.

Opinion: Promising Trajectory, Execution Is Everything

The current growth is real and policy-supported rather than purely cyclical. Domestic manufacturing share has meaningfully improved, exports have climbed, and high-end production of several previously imported devices has begun. Demand fundamentals—demographics, disease burden, insurance, and infrastructure—are durable. India’s cost position, engineering talent pool, and large domestic market give it structural advantages that few other emerging economies combine at this scale.

However, the easy phase of growth (volume in consumables and basic equipment, plus initial PLI-driven capacity) is giving way to a harder one. Sustainable leadership requires closing the technology and innovation gap: higher R&D intensity, stronger component ecosystems, faster and more predictable regulation aligned with global standards, better public-procurement pathways for credible domestic products, and a servicing ecosystem that matches the growing installed base. Without these, India risks remaining a strong mid-tech and consumables player rather than a broad-based global MedTech hub.

The upside is substantial if execution keeps pace with ambition. The combination of policy continuity, rising private capital, and global supply-chain shifts creates a genuine window. Firms that invest in quality systems, clinical evidence, design capability and export readiness—and policymakers who prioritise regulatory predictability, component localisation and innovation funding—will determine whether the sector realises the higher end of current projections or settles for more modest expansion.

In short, the Indian medical device industry is no longer just “promising.” It is growing, and the next decade will test whether that growth becomes transformative. The ingredients are present; the outcome will depend on depth of capability, not merely scale of production.